Published in Acta Med Scand on December 28, 1974
How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol (1982) 1.51
Controlled study of atenolol in treatment of hypertension. Br Med J (1975) 1.41
Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension. Br Med J (1976) 0.99
Arterial hemodynamics in human hypertension. J Clin Invest (1986) 0.98
Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients. Br Heart J (1979) 0.94
Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol (1982) 0.91
Effect of propranolol on sympathetically mediated leg vasoconstriction in humans. J Physiol (2007) 0.91
Haemodynamic effects of cigarette smoking during chronic selective and non-selective beta-adrenoceptor blockade in patients with hypertension. Br J Clin Pharmacol (1981) 0.89
Acute β-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes. Hypertension (2011) 0.84
Are different hemodynamic patterns of antihypertensive drugs clinically important? Eur J Clin Pharmacol (1990) 0.84
The influence of propranolol on the cardiovascular effects and plasma clearance of epinephrine. Anesth Prog (1992) 0.83
Haemodynamic effects of beta-adrenorecptor blockers in hypertension. Drugs (1976) 0.81
Acute effects of propranolol on the circulation and on oxygen uptake in conscious rats. Br J Pharmacol (1981) 0.78
Effects of carvedilol on renal function. Eur J Clin Pharmacol (1990) 0.76
The action of propranolol on factors concerned with the delivery of oxygen to the tissues. Br J Pharmacol (1981) 0.76
Enalapril in essential hypertension. Drugs (1985) 0.75
Antihypertensive effect and degree of beta-adrenoceptor blockade after short-term and semi-chronic propranolol therapy. Br J Clin Pharmacol (1984) 0.75
Molecular analysis of commensal host-microbial relationships in the intestine. Science (2001) 12.04
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57
Coronary heart-disease after treatment of hypertension. Lancet (1978) 3.78
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J (1973) 2.87
Comparison of performance of various sphygmomanometers with intra-arterial blood-pressure readings. Br Med J (1978) 2.72
1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens (1999) 2.72
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension (1998) 2.31
Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J (1973) 2.17
Home blood pressure determination. Value in borderline ("labile") hypertension. JAMA (1974) 2.16
Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand (1973) 2.10
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press (1993) 2.03
The present medical database needs reorganization. It's time for a change! Arch Intern Med (1990) 2.02
Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med (1998) 2.01
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol (2001) 1.94
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens (1992) 1.73
Home blood pressure monitoring. Arch Intern Med (2000) 1.71
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press (1994) 1.70
Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J (1979) 1.67
[There is no reason to avoid calcium antagonists in hypertension]. Lakartidningen (1996) 1.62
High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med (1999) 1.62
Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med (1998) 1.57
Heart rate and the cardiovascular risk. J Hypertens (1997) 1.57
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients. Br J Clin Pharmacol (1984) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy. J Hum Hypertens (2003) 1.51
Capsaicin-induced cough in humans. Am Rev Respir Dis (1992) 1.49
Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens (2005) 1.49
Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension (1993) 1.48
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens (2000) 1.48
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens (1992) 1.48
A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med (1994) 1.46
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Organization and efficacy of an out-patient hypertension clinic. Acta Med Scand (1978) 1.45
Lead, hypertension, and the renin-angiotensin system in rats. J Lab Clin Med (1982) 1.45
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens (2008) 1.44
Noise as a contributory factor in the development of elevated arterial pressure. A study of the mechanisms by which noise may raise blood pressure in man. Acta Med Scand (1980) 1.42
Controlled study of atenolol in treatment of hypertension. Br Med J (1975) 1.41
Test characteristics of the Hopkins Symptom Check List-25 (HSCL-25) in Sweden, using the Present State Examination (PSE-9) as a caseness criterion. Soc Psychiatry Psychiatr Epidemiol (1993) 1.36
Twice-daily propranolol treatment for hypertension. Lancet (1971) 1.31
Diagnostic significance of abdominal murmurs. N Engl J Med (1967) 1.29
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens (1997) 1.28
Relationship between cardiac output and peripheral resistance in borderline hypertension. Circulation (1971) 1.23
Influence of age on the hemodynamic response to exercise. Circulation (1967) 1.22
Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension (1997) 1.22
Clonidine overdose. Br Med J (1975) 1.21
A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol. Eur J Clin Pharmacol (1976) 1.21
Malignant hypertension--improving prognosis in a rare disease. Acta Med Scand (1979) 1.21
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens (2001) 1.19
Propranolol given twice daily in hypertension. Acta Med Scand (1973) 1.19
Mild high-renin essential hypertension. Neurogenic human hypertension? N Engl J Med (1977) 1.18
Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. Q J Med (1979) 1.18
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
Bulbar and suprabulbar control of the cardiovascular autonomic effects during arterial hypoxia in the rabbit. Circ Res (1970) 1.16
Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens (1984) 1.16
STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension. Blood Press (1993) 1.15
Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation (1971) 1.15
STOP-Hypertension--preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension. J Hypertens Suppl (1987) 1.14
Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens (1990) 1.13
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol (2001) 1.12
Hemodynamic studies in patients with borderline blood pressure elevation. Circulation (1968) 1.11
Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl (1973) 1.10
Objective social outcomes index (SIX): a method to summarise objective indicators of social outcomes in mental health care. Acta Psychiatr Scand (2008) 1.10
Hemodynamic responses to tilt and beta-adrenergic blockade in young patients with borderline hypertension. Circulation (1970) 1.10
Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation (1994) 1.10
Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol (2001) 1.10
Hypertension in the elderly. Hypertension seminars at Ostra Hospital, Göteborg, Sweden. Acta Med Scand (1981) 1.09
Prolonged exposure to a stressful stimulus (noise) as a cause of raised blood-pressure in man. Lancet (1977) 1.09
Relationships between metrics of visit-to-visit variability of blood pressure. J Hum Hypertens (2013) 1.08
Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade. J Hypertens Suppl (1983) 1.08
Does drug treatment improve survival in mild-to-moderate hypertension? J Hypertens (1995) 1.07
Relation of maternal blood pressure during pregnancy to birth weight and blood pressure in children. The Hypertension in Pregnancy Offspring Study. J Intern Med (1994) 1.07
Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class. Int J Clin Pract (2011) 1.07
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension (2000) 1.07
Changes in glycosylation of human bile-salt-stimulated lipase during lactation. Arch Biochem Biophys (2000) 1.07
Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med (1990) 1.06
Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control (1997) 1.06
Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens (1997) 1.06
Accuracy of Borg's ratings of perceived exertion in the prediction of heart rates during pregnancy. Br J Sports Med (1992) 1.06
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. Acta Med Scand (1983) 1.05
The peripheral circulatory effects of clonidine and their role in the production of arterial hypotension. Eur J Pharmacol (1971) 1.05
Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens (1996) 1.04
The relationship between pulse volume and blood flow in the finger. Angiology (1967) 1.03
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects. Blood Press Monit (1999) 1.03
Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med (1972) 1.03
The Nordic Study on schizophrenic patients living in the community. Subjective needs and perceived help. Eur Psychiatry (2001) 1.02
Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens (2000) 1.02
The validity of Antonovsky's Sense of Coherence measure in a sample of schizophrenic patients living in the community. J Adv Nurs (2001) 1.02
Prediction of later hypertension following a hypertensive pregnancy. J Hypertens Suppl (1983) 1.02
Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest (1987) 1.02